Fierce Drug Dev Forum 2019 has ended
avatar for Stefan Irion, M.D.

Stefan Irion, M.D.

Vice President, Translational Neuroscience
Stefan Irion, M.D., joined BlueRock bringing deep knowledge of cell therapies from his research experience in both academia and industry. Dr. Irion has been working on the development team for BlueRock’s lead cellular therapeutic candidate targeting Parkinson’s disease since 2013, when he served as program manager at Memorial Sloane Kettering. He transitioned to BlueRock in 2017, assuming management of the neurology program in house. Prior to Memorial Sloane Kettering, Dr. Irion worked as a senior scientist and project team leader at iPierian, a role in which he developed an induced pluripotent stem cell model of Alzheimer’s disease that led to the discovery of a novel anti-tau antibody. Bristol-Myers Squibb acquired iPierian in a $725M deal in 2014. Dr. Irion was previously a postdoctoral fellow at the University Health Network, specializing in cell biology and gene targeting, and at the Mount Sinai School of Medicine. He holds an M.D. from the University of Tübingen in Germany.

My Speakers Sessions

Monday, October 28